Prolonged TAXOL exposure improves anti-cancer therapy
TOKYO, Sept. 13 - New data shows that patients with advanced lung cancer may have a safer chemotherapy treatment option. The use of TAXOL (paclitaxel) plus Paraplatin (carboplatin), administered in a novel weekly regimen, offers a safe and effective treatment option for patients with advanced lung cancer, according to research presented today at the 9th World Conference on Lung Cancer. Safety and tolerability are of critical importance in patients with advanced lung cancer.
"These data show that the use of weekly TAXOL plus Paraplatin provides a very tolerable treatment for patients with advanced lung cancer," reported Chandra Belani, M.D., lead investigator of the study, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute (UPCI). "The tolerability of weekly TAXOL in advanced non-small cell lung cancer (NSCLC) patients suggests that this regimen may be a favorable option. This could also represent an alternative treatment option for the elderly."
The study enrolled patients with untreated advanced NSCLC. It was designed to evaluate three different regimens of weekly TAXOL plus Paraplatin followed by a further randomization of patients to either weekly TAXOL or observation, based on response.
Preliminary results of this phase II study suggest that a regimen of four cycles of TAXOL (100 mg/m2) administered weekly for three weeks, with the fourth week off, plus Paraplatin (AUC=6) administered on day one of each cycle (arm A), is the most tolerable regimen compared to the other weekly TAXOL plus Paraplatin regimens for these NSCLC patients. Patients on this regimen also experienced less neurotoxicity. Preliminary analyses also show that this regimen was associated with fewer deaths. Also, only 3 percent of patients receiving weekly TAXOL plus Paraplatin experienced grade 3-4 neuropathy.